Analyst Price Targets — IPHA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 29, 2025 10:09 am | — | H.C. Wainwright | $5.00 | $2.09 | TheFly | Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright |
| September 17, 2025 10:35 pm | — | Leerink Partners | $2.00 | $2.05 | TheFly | Innate Pharma downgraded to Market Perform from Outperform at Leerink |
Latest News for IPHA
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at…
MARSEILLE, France--(BUSINESS WIRE)-- #Actionnaires--Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026.
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 9, 2026.
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients. Yannis Morel will present in the Showcase Session 2 on Thursday, April 16, 2026, at 6:10 PM PDT, at the San Diego…
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Kempen Life Sciences conference.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for IPHA.
Senate Trading
No Senate trades found for IPHA.
U.S. House Trading
No House trades found for IPHA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.